MAIA Biotechnology Obtains FDA Clearance To Extend Go-to-market THIO-101 Trial To The U.S.

(RTTNews) - MAIA Biotechnology, Inc. (MAIA) announced the FDA has cleared Investigational New Drug application for THIO to be evaluated in the U.S. as part of THIO-101, the company's ongoing global phase 2 clinical study in patients with advanced Non-Small Cell Lung Cancer. THIO is being tested in sequential combination with Regeneron's anti PD-1 monoclonal antibody cemiplimab to evaluate anti-tumor activity and immune response in NSCLC patients.

"The FDA IND clearance represents an essential milestone in the clinical development of THIO," said Mihail Obrocea, MAIA's Chief Medical Officer.

For More Such Health News, visit rttnews.com.